Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

ClinicalTrials.gov ID: NCT04280718

Public ClinicalTrials.gov record NCT04280718. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.

Study identification

NCT ID
NCT04280718
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
argenx
Industry
Enrollment
229 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 18, 2020 (Actual)
Primary completion
Apr 30, 2027 (Estimated)
Completion
Apr 30, 2027 (Estimated)
Last update posted
Jun 29, 2025

2020 – 2027

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
24
Facility City State ZIP Site status
Investigator site 0010065 Birmingham Alabama 35233-2110 —
Investigator site 0010013 Phoenix Arizona 85018 —
Investigator site 0010055 Scottsdale Arizona 85028 —
Investigator site 0010032 Carlsbad California 92011 —
Investigator site 10190 Pomona California 91767-2009 —
Investigator site 0010160 Rancho Mirage California 92270-4150 —
Investigator site 0010071 San Francisco California 94109 —
Investigator site 0010057 Centennial Colorado 80112 —
Investigator site 0010072 Boca Raton Florida 33487 —
Investigator site 0010144 Coral Springs Florida 33067-4640 —
Investigator site 0010023 Jacksonville Florida 32209 —
Investigator site 0010068 Maitland Florida 32751 —
Investigator site 0010059 Miami Florida 33136 —
Investigator site 0010006 Tampa Florida 33612 —
Investigator site 0010011 Iowa City Iowa 52242 —
Investigator site 0010015 Fairway Kansas 66205 —
Investigator site 10147 Lexington Kentucky 40536 —
Investigator site 10168 New York New York 10016 —
Investigator site 0010003 Chapel Hill North Carolina 27517 —
Investigator site 0010064 Columbus Ohio 43210 —
Investigator site 0010007 Philadelphia Pennsylvania 19107 —
Investigator site 0010047 Philadelphia Pennsylvania 19126 —
Investigator Site 0010066 Austin Texas 78756 —
Investigator site 0010009 San Antonio Texas 78229 —
Investigator site 0010061 Richmond Virginia 23298 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04280718, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2025 · Synced Oct 31, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04280718 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →